A Mini-review on Helicobacter pylori with Gastric Cancer and Available Treatments

Endocr Metab Immune Disord Drug Targets. 2024;24(3):277-290. doi: 10.2174/1871530323666230824161901.

Abstract

Helicobacter pylori (H. pylori) is the most thoroughly researched etiological component for stomach inflammation and malignancies. Even though there are conventional recommendations and treatment regimens for eradicating H. pylori, failure rates continue to climb. Antibiotic resistance contributes significantly to misdiagnoses, false positive results, and clinical failures, all of which raise the chance of infection recurrence. This review aims to explore the molecular mechanisms underlying drug resistance in H. pylori and discuss novel approaches for detecting genotypic resistance. Modulation of drug uptake/ efflux, biofilm, and coccoid development. Newer genome sequencing approaches capable of detecting H. pylori genotypic resistance are presented. Prolonged infection in the stomach causes major problems such as gastric cancer. The review discusses how H. pylori causes stomach cancer, recent biomarkers such as miRNAs, molecular pathways in the development of gastric cancer, and diagnostic methods and clinical trials for the disease. Efforts have been made to summarize the recent advancements made toward early diagnosis and novel therapeutic approaches for H. pylori-induced gastric cancer.

Keywords: Helicobacter pylori; antibiotic resistance; gastric cancer; miRNAs; multidrug resistance; new genome sequencing techniques..

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / therapeutic use
  • Drug Resistance, Bacterial
  • Helicobacter Infections* / diagnosis
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / microbiology
  • Helicobacter pylori* / drug effects
  • Helicobacter pylori* / genetics
  • Humans
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / microbiology

Substances

  • Anti-Bacterial Agents